Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Conavi Medical ( (TSE:CNVI) ) has shared an announcement.
Conavi Medical announced its participation in the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference, where it will showcase its Novasight Hybrid™ imaging technology. This technology, which combines IVUS and OCT, offers enhanced insights into coronary anatomy and aids in guiding complex percutaneous coronary interventions (PCI). The company will also engage in educational sessions to demonstrate the application of intravascular imaging in challenging PCI procedures. The next-generation Novasight Hybrid system is currently under review for FDA clearance, indicating potential advancements in Conavi’s market presence and impact on interventional cardiology.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a commercial-stage medical device company specializing in intravascular imaging solutions. It designs, manufactures, and markets imaging technologies to guide minimally invasive cardiovascular procedures. The company’s patented Novasight Hybrid™ System uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device for simultaneous imaging of coronary arteries. The first-generation system has received regulatory clearance in the U.S., Canada, China, and Japan.
Average Trading Volume: 30,630
Technical Sentiment Signal: Sell
Current Market Cap: C$32.07M
For an in-depth examination of CNVI stock, go to TipRanks’ Overview page.